Figures & data
Table I. Recommended first-line therapy for HIV-infected treatment-naive patients in 2010.
Table II. Outcomes of boosted protease inhibitor comparator trials in HIV-infected treatment-naive patients at 48 weeks.
Annals of Medicine
Volume 43, 2011 - Issue 5
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related Research Data
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.
Source:
Elsevier BV
Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients
Source:
Oxford University Press (OUP)
Binding Kinetics of Darunavir to Human Immunodeficiency Virus Type 1 Protease Explain the Potent Antiviral Activity and High Genetic Barrier
Source:
American Society for Microbiology
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
Source:
Ovid Technologies (Wolters Kluwer Health)
A 96-Week Comparison of Lopinavir- Ritonavir Combination Therapy Followed by Lopinavir-Ritonavir Monotherapy versus Efavirenz Combination Therapy
Source:
Oxford University Press (OUP)
Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro
Source:
American Society for Microbiology
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
Source:
Massachusetts Medical Society
Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients
Source:
Oxford University Press (OUP)
The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.
Source:
Ovid Technologies (Wolters Kluwer Health)
Pharmacokinetic enhancement of protease inhibitors.
Source:
Ovid Technologies (Wolters Kluwer Health)
COMPARISON OF ONCE-DAILY VERSUS TWICE-DAILY COMBINATION ANTIRETROVIRAL THERAPY IN TREATMENT-NAÏVE PATIENTS: RESULTS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5073, A 48-WEEK RANDOMIZED CONTROLLED TRIAL
Source:
Oxford University Press (OUP)
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.
Source:
Mary Ann Liebert Inc
Boosting of HIV Protease Inhibitors by Ritonavir in the Intestine: The Relative Role of Cytochrome P450 and P-Glycoprotein Inhibition Based on Caco-2 Monolayers versus In Situ Intestinal Perfusion in Mice
Source:
American Society for Pharmacology & Experimental Therapeutics (ASPET)
absence of protease resistance at 48 weeks
Source:
Ovid Technologies (Wolters Kluwer Health)
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
Source:
Oxford University Press (OUP)
Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients.
Source:
Informa UK Limited
The INCAS Trial
Source:
American Medical Association (AMA)
48-Week Results of a Randomized, Controlled, Open-Label, Proof-of-Concept Pilot Clinical Trial (OK Study)
Source:
Ovid Technologies (Wolters Kluwer Health)
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Source:
Ovid Technologies (Wolters Kluwer Health)
A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen.
Source:
Ovid Technologies (Wolters Kluwer Health)
Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir
Source:
Springer Science and Business Media LLC
Comparison of Four-Drug Regimens and Pairs of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection
Source:
Massachusetts Medical Society
Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511)
Source:
Ovid Technologies (Wolters Kluwer Health)
Visceral abdominal-fat accumulation associated with use of indinavir
Source:
Elsevier BV
Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection
Source:
The University of North Carolina at Chapel Hill University Libraries
Nelfinavir Mesylate: A Protease Inhibitor
Source:
SAGE Publications
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
Source:
Proceedings of the National Academy of Sciences
A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience
Source:
Ovid Technologies (Wolters Kluwer Health)
Treatment with Amprenavir Alone or Amprenavir with Zidovudine and Lamivudine in Adults with Human Immunodeficiency Virus Infection
Source:
Oxford University Press (OUP)
Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.
Source:
Ovid Technologies (Wolters Kluwer Health)
In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents
Source:
Elsevier BV
Pharmacology, Efficacy and Tolerability Profile
Source:
Springer Science and Business Media LLC
Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected Patients
Source:
American Society for Microbiology
Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir
Source:
American Society for Microbiology
The Effect of High-Dose Saquinavir on Viral Load and CD4+ T-Cell Counts in HIV-Infected Patients
Source:
American College of Physicians
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
Source:
Massachusetts Medical Society
In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors.
Source:
Ovid Technologies (Wolters Kluwer Health)
Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial.
Source:
Springer Nature
Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society-USA Panel
Source:
University of Chicago Press
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
Source:
Ovid Technologies (Wolters Kluwer Health)
Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.
Source:
Ovid Technologies (Wolters Kluwer Health)
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
Source:
Massachusetts Medical Society
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Source:
Ovid Technologies (Wolters Kluwer Health)
Low-dose ritonavir moderately enhances nelfinavir exposure
Source:
Springer Science and Business Media LLC
TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates
Source:
American Society for Microbiology
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
Source:
Ovid Technologies (Wolters Kluwer Health)
Genetic locus, primary structure, and chemical synthesis of human immunodeficiency virus protease.
Source:
Elsevier BV
Class of antiretroviral drugs and the risk of myocardial infarction.
Source:
Massachusetts Medical Society
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
Source:
Ovid Technologies (Wolters Kluwer Health)
The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.
Source:
Ovid Technologies (Wolters Kluwer Health)
Plasma Levels of Atazanavir and the Risk of Hyperbilirubinemia Are Predicted by the 3435C→T Polymorphism at the Multidrug Resistance Gene 1
Source:
Oxford University Press (OUP)
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults
Source:
Springer Science and Business Media LLC
Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy
Source:
American Medical Association (AMA)
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
Source:
Massachusetts Medical Society
Linking provided by
